6-benzylamino-2-(2-hydroxyethylamino)-9-methylpurine-1,7-diium bis(perchlorate) monohydrate

被引:10
作者
Trávnícek, Z
Krystof, V
机构
[1] Palacky Univ, Fac Sci, Dept Inorgan Chem, CZ-77147 Olomouc, Czech Republic
[2] Palacky Univ, Inst Expt Bot, CZ-78371 Olomouc, Czech Republic
[3] Palacky Univ, Lab Growth Regulators, CZ-78371 Olomouc, Czech Republic
来源
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE | 2004年 / 60卷
关键词
D O I
10.1107/S160053680402896X
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
The title compound, C15H20N6O2+ . 2ClO(4)(-).H2O, belongs to a group of cytokinin-derived compounds. It has been found that some cytokinin derivatives, e. g. 2,6,9-trisubstituted purine derivatives, behave as potent inhibitors of cyclin-dependent kinases (CDKs) and show anticancer activity. Olomoucine, i.e. the title cation in its neutral form, represents one of the first CDK specific inhibitors that selectively blocks CDK1, CDK2 and CDK5 kinases at micromolar concentrations. The asymmetric unit of the title compound consists of the diprotonated cation, two perchlorate anions and a water molecule of crystallization. The cation contains nearly planar benzene and purine ring systems, the dihedral angle between them being 46.77 (6) degrees. The crystal structure is stabilized by N-purine - H ... O-water/O-hydroxy, N-amine - H ... O-water/O-hydroxy, O-water - H ... O-perchlorate and O-hydroxy - H ... O-perchlorate hydrogen bonds.
引用
收藏
页码:O2324 / O2327
页数:4
相关论文
共 25 条
[1]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[2]  
Burnett M.N., 1996, ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for Crystal Structure Illustrations
[3]   2,6,9-trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors [J].
Imbach, P ;
Capraro, HG ;
Furet, P ;
Mett, H ;
Meyer, T ;
Zimmermann, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (01) :91-96
[4]   Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases [J].
Kotala, V ;
Uldrijan, S ;
Horky, M ;
Trbusek, M ;
Strnad, M ;
Vojtesek, B .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (09) :1333-1339
[5]   Synthesis, characterization and antitumour activity of copper(II) 6-(4-chlorobenzylamino)purine complexes.: X-ray structure of 6-(4-chloro-benzylamino)purinium perchlorate [J].
Malon, M ;
Trávnícek, Z ;
Marysko, M ;
Marek, J ;
Dolezal, K ;
Rolcík, J ;
Strnad, M .
TRANSITION METAL CHEMISTRY, 2002, 27 (06) :580-586
[6]   Metal complexes as anticancer agents 2.: Iron(III) and copper(II) bio-active complexes with N6-benzylaminopurine derivatives [J].
Malon, M ;
Trávnícek, Z ;
Marysko, M ;
Zboril, R ;
Maslán, M ;
Marek, J ;
Dolezal, K ;
Rolcík, J ;
Krystof, V ;
Strnad, M .
INORGANICA CHIMICA ACTA, 2001, 323 (1-2) :119-129
[7]   In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) [J].
McClue, SJ ;
Blake, D ;
Clarke, R ;
Cowan, A ;
Cummings, L ;
Fischer, PM ;
MacKenzie, M ;
Melville, J ;
Stewart, K ;
Wang, SD ;
Zhelev, N ;
Zheleva, D ;
Lane, DP .
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (05) :463-468
[8]   Roscovitine and other purines as kinase inhihitors. From starfish oocytes to clinical trials [J].
Meijer, L ;
Raymond, E .
ACCOUNTS OF CHEMICAL RESEARCH, 2003, 36 (06) :417-425
[9]  
Nardelli M., 1995, J APPL CRYSTALLOGR, V28, P659, DOI [10.1107/S0021889895007138, DOI 10.1107/S0021889895007138]
[10]  
*OXF DIFFR LTD, 2004, CRYSALIS RED VERS 1